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Apoptosis, also known as programmed cell death, allows 
 controlled removal of aged, damaged, infected or unwanted 
cells, maintaining homeostasis in multicellular organ-
isms. This process would be functionally ineffective with-
out clearance of resulting apoptotic corpses, as without 
disposal, they would progress to secondary necrosis and 
drive unwanted inflammation and autoimmune disease.1 
 Effective clearance of dying cells is orchestrated by a bal-
ance of pro- and anti- clearance mediators that, under nor-
mal physiological conditions, skew towards phagocytic 
clearance as apoptosis proceeds. This process typically 
results in an overall anti-inflammatory phenotype.2 How-
ever, if this balance is altered, clearance mechanisms can 
fail and pathology may ensue.
It is likely that much, and perhaps a majority of, apop-
totic cell clearance occurs before dying cells show ‘classical’ 
morphological features of apoptosis (such as the  characteristic 
nuclear changes associated with in vitro apoptotic death of 
lymphocytes—Fig. 1). Such death may be cleared by viable 
neighboring cells (e.g., epithelial cells), phagocytes that have 
often been called ‘amateur’ phagocytes, as their primary func-
tion is not phagocytosis of material (e.g., bacteria and cell 
debris).3 However, it has been suggested that perhaps these 
local cells may in fact be the ‘professional’ phagocytes of early 
apoptotic cells, and that recruited phagocytes (e.g., macro-
phages, whose primary function is phagocytosis of such mate-
rial) are the professional scavengers of dying cells that have 
failed to be cleared sooner.4 This latter situation will occur at 
sites of high level apoptosis5 and will often be associated with 
pathological situations.1
Effective clearance of dying cells requires the orches-
tration of a complex multi-stage process (Fig. 2). An early 
event, often neglected as it is not seen in simple in vitro 
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Figure 1. The classical apoptotic cell. Human B cell lines exhibit a level of spontaneous apoptosis. In this figure it is possible to compare the 
morphology of cells when stained with the nucleic acid-binding agent acridine orange (25 µg/ml). Acridine orange fluoresces green when bound to double 
stranded nucleic acid (i.e. Dna) and orange when bound to single stranded rna. the arrow highlights a viable cell nucleus and the arrowheads identify 
classically apoptotic cell nuclei. the two cells marked with an asterisk are actively growing (hence the orange cytoplasm as a result of high levels of 
mrna). the scale bar represents 10 µm.
 culture  models of apoptosis, is the recruitment of  phagocytes 
to sites of cell death. This recruitment requires the release of 
attractants from dying cells and the consequent attraction 
of phagocytes. As the recruited phagocyte recognizes the 
‘scent’ of dying cells it must migrate to and bind (i.e. tether) 
apoptotic cells prior to engulfing and degrading the cell 
corpse. Dead cell removal alone at inflammatory sites is 
insufficient to ensure resolution of cell death— emigration 
of phagocytes must also occur to restore the tissue to its 
 previous state.
Ineffective clearance of apoptotic cells may thus arise 
from a defect in any one, or more, of these stages. Defects 
in genes related to clearance of apoptotic cells are associ-
ated with a variety of disease conditions, though it is not 
always clear whether the pathology arises directly from a 
failure to remove apoptotic cells. However, failed clearance 
of apoptotic cells is well- established in the pathogenesis of 
 autoimmune disease, as persistent apoptotic cells ultimately 
lose their membrane integrity, thus promoting the produc-
tion of autoantibodies to usually sequestered  intracellular 
antigens that are released from necrotic cells. For example, 
defects in C1q expression (a  soluble complement compo-
nent known to opsonise apoptotic cells and mediate efficient 
corpse clearance) can drive systemic lupus erythematosus.6 
Furthermore, increased incidence of apoptotic cells is also 
noted in range of inflammatory lung diseases (reviewed in7). 
Failed clearance of dying cells has also been implicated in 
inflammation associated with aging8 and a number of age-
related conditions, including arthritis, neuropathy and 
atherosclerosis (reviewed in1). Atherosclerosis, the major 
pathology focus of this review, represents an important in 
vivo example of a site of high level cell death that is associ-
ated clearly with defective apoptotic cell clearance and failed 
emigration of phagocytes.
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Figure 2. Apoptotic cell clearance—a multi-stage process. a schematic diagram of the basic phases of apoptotic cell clearance and a summary 
of molecular players in these phases. PhaGoCYte reCruItMent: Stressed cells and those undergoing apoptosis release signals (soluble and 
associated with extracellular vesicles (eV)) to recruit phagocytes to sites of cell death. reCoGnItIon: Initial phagocyte-apoptotic cell contacts that 
may lead to firm TETHERING. In these phases it is likely that some molecules mediate both recognition and tethering. SIGNALLING & ENGULFMENT: 
receptor-ligand interactions induce phagocyte responses including immuno-modulatory signalling and signalling for engulfment (phagocytosis). 
recognition of PS mediates recognition, tethering and signalling/engulfment but different phases are mediated by different PS receptors (e.g. tim-4 is 
proposed to function in tethering whilst BaI-1 can mediate engulfment).
Within developing atherosclerotic plaques, large  numbers 
of monocytes/macrophages are recruited to remove dying 
‘foam’ cells (lipid-laden macrophages). However, with a  failure 
in clearance and lack of phagocyte egress, further  phagocyte 
recruitment exacerbates the problem. Collectively these events 
drive this important pathology,9,10 which is, perhaps, a key tar-
get for therapeutic intervention based on a detailed understand-
ing of the mechanisms associated with apoptotic cell clearance. 
As risk factors for atherosclerosis, such as aging and obesity, are 
on the increase in the general population, it is imperative to gain 
a full understanding of cell clearance mechanisms, which may 
aid future management and treatment of these conditions.11
This article will outline the molecular and cellular 
 mechanisms proposed to function in concert for the efficient 
removal of apoptotic cells in vivo by monocytes and macro-
phages, and will highlight areas that require further study 
to address the role of apoptotic cell removal in important 
 pathological situations such as cardiovascular disease.
Dealing with Death—the Janitors
Macrophages are inherently plastic, switching phenotype in 
response to the local microenvironment. Classically-activated 
‘M1’ macrophages are associated with a pro-inflammatory 
phenotype; for example, in response to pathogenic stimuli, 
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referred to as microparticles) and was, until recently, the 
only classical chemokine implicated in the recruitment of 
phagocytes to dying cells. It ligates the receptor CX3CR1 on 
the phagocyte surface to promote directional migration.15,19 
CX3CL1 also increases expression of milk fat globule-
endothelial growth factor 8 (MFG-E8), an identified bridg-
ing molecule between apoptotic cells and phagocytes, thus 
enhancing clearance.20 More recently, however, cells induced 
to apoptosis through ligation of Fas/CD95 have been shown 
to release an array of cytokines and chemokines includ-
ing MCP-1 and IL-8 that were demonstrated to be attrac-
tive to THP-1 monocytes and primary human neutrophils 
respectively.21
Lysophosphatidylcholine (LPC) is a lipid mediator asso-
ciated with phagocyte recruitment to dying cells22 via inter-
action with the G-protein-coupled receptor (GPCR) receptor 
G2A.23,24 Whilst its precise role has been questioned, mice 
defective in the ‘find me’ signal receptor G2A develop an auto-
immune syndrome.25 It may be most important as an autocrine 
effector molecule, as it has been shown to induce expression 
of monocyte, neutrophil and lymphocyte chemoattractants 
monocyte chemotactic protein-1 (MCP-1),  interleukin-8 
(IL-8) and chemokine (C-C motif) ligand 5 (CCL5).26 Sphin-
gosine-1-phosphate (S1P) is another lipid mediator with roles 
as both a chemoattractant and immune-modulator. Interact-
ing with GPCRs on the phagocyte, S1P also induces IL-8 and 
IL-10 release, whilst reducing tumor necrosis factor-α (TNF-
α) and IL-12p70 production.27–29
Nucleotides such as ATP and UTP have been pro-
posed to be short-range chemoattractants, interacting with 
 purinoreceptor-2 (P2Y2) on the phagocyte surface.30 The 
possible short range of action of these attractants highlights 
the likelihood that multiple attractants will work together in 
effecting the efficient homing of phagocytes to sites of cell 
death. Whether some attractants are more active than oth-
ers on different sub-populations of phagocytes remains to 
be determined, but these studies are necessary to provide a 
full picture of the mechanisms at work within the clearance 
of apoptotic cells. Recent work has also suggested that oxi-
dative stress, even without cell death, may mediate selective 
recruitment of monocytes.31 Such attraction to stressed, but 
not dying cells, may be a physiologically relevant mechanism 
by which phagocytes are deployed in readiness for cell deaths, 
though this may also promote disease.
Many of these chemoattractants, e.g., CX3CL1, are 
packaged in association with extracellular vesicles released 
following zeiosis, or blebbing, of the apoptotic cell mem-
brane. Thus, extracellular vesicles play a key role in phago-
cyte recruitment.15,32 Torr et al (2012) demonstrated that 
the reduction in apoptotic cell surface intercellular adhesion 
molecule (ICAM)-3 was the result of its shedding on extra-
cellular vesicles.33 These vesicles were shown to be attractive 
to phagocytes in an ICAM-3-dependent manner. This effect 
was demonstrated using a vertical migration chamber where 
whereas alternatively-activated ‘M2’ macrophages have a 
more reparative role, with functions in apoptotic cell removal 
and resolution of inflammation.12 Researchers have tried to 
designate macrophage phenotypes according to characteris-
tic responses and receptor profiles, but it is becoming clear 
that rather than definitive subtypes, macrophages exhibit 
a spectrum of activity that can continually alter, depend-
ing upon their microenvironment (reviewed in13). Conse-
quently, the macrophage phenotype will likely be crucial to 
the ultimate outcome arising from sites of cell death, with 
non-resolving chronic inflammatory sites supporting inflam-
matory phenotypes. Apoptotic cells are known to modulate 
the phenotype of phagocytes towards an anti-inflammatory 
phenotype.2
Macrophages are often recruited from circulating blood 
monocytes rather than long-lived tissue-resident macro-
phages. This is particularly true of macrophages infiltrat-
ing atheromatous plaques. Monocyte subtypes are highly 
studied, with surface receptors (CD14, CD16 and chemo-
kine receptors e.g. CX3CR1) utilized to identify distinct 
phenotypic subgroups.14 Expression of classical chemokine 
receptors may define those monocyte populations recruited 
to sites of cell death but detailed studies of recruited mono-
cytes are still to be fully undertaken. This may be crucially 
important to outcome. CX3CL1, released in association 
with apoptotic cell-derived extracellular vesicles, has been 
shown to function as a chemoattractant for phagocytes.15 
This identifies CX3CR1high monocytes as an interesting 
research target in the field of apoptotic cell clearance, espe-
cially as CX3CR1 and CX3CL1 are both expressed on foam 
cells16 and CX3CR1 is involved in monocyte recruitment to 
the atherosclerotic plaque,17 a site of defective cell clearance 
(reviewed in18).
Phagocyte Recruitment—‘Find me’ Versus ‘Keep out’
In the case of professional phagocyte (i.e. monocyte/ 
macrophage) recruitment, evidence indicates clearly that 
‘find me’ signals are released by apoptotic cells, either as 
soluble molecules or as part of complex extracellular vesicles. 
This relatively new area of apoptotic cell research addresses 
phagocyte migration to dying cells in a manner that is 
relevant to the in vivo clearance of apoptotic cells. In the 
past, apoptotic cell clearance studies have often relied upon 
a simple assay system where apoptotic cells were ‘fed’ to 
phagocytes in the presence or absence of putative blocking 
antibodies. Whilst fruitful, current in vitro studies are now 
directed to address the full extent of the processes within the 
apoptotic cell clearance program. Several different classes 
of attractant have now been identified as ‘find me’ signals 
released by apoptotic cells. Deficiencies, outlined below, in 
some of these signals or their receptors have been linked to 
inflammatory conditions.
CX3CL1 (fractalkine) is released by apoptotic human 
B  cells in association with extracellular vesicles (often 
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cells. Some examples of these signals are IL-8 released from 
 Fas-mediated apoptosis of epithelial cells or LPC-induced 
IL-8 production in endothelial cells.21,26 Lactoferrin may pro-
vide an answer as to why neutrophilic infiltrates are not found 
at sites of persistent apoptosis. Lactoferrin acts as a ‘keep out’ 
signal, deterring granulocyte migration.35,36 This highlights 
again the need for balance between the mixed messages 
being relayed by apoptotic cells in order to maintain effective, 
immunologically-silent clearance, and further ‘keep out’ sig-
nals could yet be discovered.
The lineage of recruited phagocytes (e.g., granulocyte 
versus mononuclear) and their phenotype may be central to 
the elicited response at sites of cell death and the balance of 
‘find me’ and ‘keep out’ signals will control this. Thus the 
ability to tip the balance in favor of ‘keep out’ signals repre-
sents an attractive therapeutic option to inhibit recruitment 
of phagocytes where this is not beneficial. For example, lac-
toferrin is known to reduce the migration of neutrophilic35 
and eosinophilic36 granulocytes, and thus may be developed 
for the therapy of inflammatory conditions where granulo-
cyte recruitment causes more harm than good.37 For example, 
targeting of eosinophil apoptosis and clearance has been dis-
cussed in a recent review as possible intervention for asthma38 
and prevention of granulocyte recruitment may represent a 
therapeutic strategy.36
Despite recruitment of phagocytes to apoptosis, there are 
sites of cell death that do not resolve (i.e., where the focus 
of cell death is not removed). The atherosclerotic plaque is 
a prime example of one such non-resolving  inflammation. 
gravity exerts its effects in ‘driving’ phagocytes towards 
apoptotic cells in a lower chamber. Chemotaxis is modeled 
with varying success in vitro. Models are often highly sim-
plified and results confounded by poor chemotactic gradi-
ents (e.g., ‘all  or  nothing’ step gradients in transwell-based 
assays) and the impact of gravity. Routinely now, horizontal 
migration chambers with time-lapse video microscopy can 
be used that rely on true chemotactic gradients and remove 
the impact of gravity on the assay. In these assay systems, 
phagocyte migration towards apoptotic cells can be clearly 
revealed and measures of phagocyte speed and direction can 
be made (Fig. 3).
A limited number of molecules (e.g., ICAM-3 and 
CX3CL1) on apoptotic cell-derived extracellular vesicles have 
been identified to promote phagocyte attraction, and a full 
analysis of the physicochemical characteristics and molecu-
lar constitution (proteome, lipidome and glycome) has yet 
to be undertaken. This approach will likely yield important 
information that will pave the way to manipulating phagocyte 
recruitment. Furthermore, little is known of the cargo associ-
ated with the extracellular vesicles, though cargo carried by 
extracellular vesicles from other sources are known to have 
profound biological effects (reviewed in34).
The nature of recruited phagocytes must also be managed 
carefully at sites of cell death due to the inflammatory nature 
of some phagocyte populations, and is a key stage with regards 
to immunological outcome. Some apoptotic cell-derived 
‘find me’ signals are capable of recruiting neutrophils, which 
would result in an undesirable phlogistic reaction to apoptotic 
Figure 3. Migration of the human monocyte line (THP-1) towards apoptotic cell-derived extracellular vesicles. thP-1 cells were seeded to 
coverslips and stimulated to differentiate with dihydroxyvitamin D3 (100 nM; 48 h) before being loaded to a Dunn chemotaxis chamber. thP-1 cells were 
exposed to extracellular vesicles derived from apoptotic human B cells that were ICAM-3 replete (WT-left panel), ICAM-3-deficient33 (centre panel) or no 
attractant (right panel). Cells were studied using time-lapse imaging phase contrast microscopy (Zeiss axiovert motorized microscope) over 2 hours and 
cell migration tracked using ImageJ software. The track of each cell is shown, starting at the cross hairs and finishing at a black dot. All plots are shown 
on the same scale. the position of the attractant is shown at the top of each plot (red dot).
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Phagocyte recruitment to important pathological sites 
(e.g., the atherosclerotic plaque) still requires further research. 
Sites such as these are difficult to model in vitro, with much 
of the work done in animal models; however, mechanisms 
between species are not always conserved, leaving gaps in 
research areas where murine models are prominent. For exam-
ple, ICAM-3, which is released from apoptotic cells in asso-
ciation with extracellular vesicles and promotes  macrophage 
recruitment to apoptotic cells, is absent from rodents. It is also 
unclear whether ‘find me’ signals and/or apoptotic cell-derived 
extracellular vesicles from foam cell death activate endothe-
lium to recruit leukocytes, and which attractants are key to 
monocytes finding apoptotic cells within the plaque following 
transmigration.
Recognition and Tethering—‘Eat me’ Versus 
‘Don’t Eat me’
In order for phagocytes to begin the clearance process, target 
cells must be recognized as apoptotic. Recognition is the first 
stage of a 4-stage model,4 followed by tethering (binding), 
tickling (signaling) and finally phagocytosis. Figure 4 shows 
a typical presentation of a human monocyte-derived macro-
phage associated with apoptotic cells. The molecular players 
involved in these processes have been extensively reviewed 
elsewhere4,9,45 and so will be covered relatively briefly in this 
This pathological situation highlights how continued phago-
cyte recruitment may not be beneficial; phagocytes enter the 
plaque and remove dying cells, but this phagocytic clearance 
has been suggested to be defective.18,39 The phagocytes also 
become trapped at this site such that they ultimately die by 
 apoptosis, leading to further monocyte recruitment.10,40 It has 
been suggested that oxidized LDL within the plaque envi-
ronment may upregulate CX3CL1 expression, preventing 
macrophage egress,16 whilst macrophage emigration from the 
plaque is also prevented by netrin-1.10 Thus, when balance in 
phagocyte recruitment fails, it may lead to pathologies such 
as those in atherosclerosis, where either over-recruitment or 
a lack of cell egress contribute to pathology (reviewed in40). 
Consequently, this site could benefit from modulation of 
the monocyte recruitment phase of apoptotic cell clearance. 
This may occur through recruitment of alternative phagocyte 
 subsets— evidence suggests that monocyte sub- populations 
may influence disease, with sub-population counts being 
predictors of disease.41–43 It may also be through blockade of 
recruitment such that the pathology, whilst not resolved, is 
halted in its progression. Targets for effecting such modula-
tion might include CX3CL1, ICAM-3 and other ‘find me’ 
signals or ‘keep out’ signals. In support of this, mice defective 
in CX3CR1 show both reduced plaque size and phagocyte 
accumulation.44
Figure 4. Binding of apoptotic cells by human monocyte-derived macrophage. the arrows indicate typical presentation of apoptotic cells 
(arrowheads) interacting with macrophages (arrow). the scale bar represents 25 µm.
Clearance of apoptotic cells 
63Journal of Cell Death 2013:6
indicating that different phagocytes for apoptotic cells will 
use a different set of receptors for clearance and they likely 
have different functions, as Tim-4 appears to solely tether 
apoptotic cells via exposed PS.60 PS on the apoptotic cell 
may also bind to phagocyte receptors indirectly through 
molecular bridges: Gas-6 and protein S bridge to MerTK 
whilst MFG-E8 bridges to αv integrins.61 The phagocyte 
receptor CD91 (LDL-receptor-related protein (LRP)) has 
been shown to bind PS when colocalized with redistributed 
calreticulin.62 Calreticulin, upregulated during apoptosis, 
also associates with bridging molecules C1q and MBL for 
recognition by LRP.54 Modification of PS, by mechanisms 
such as oxidation, also allows binding to phagocytic scav-
enger receptors such as CD36.63 Scavenger receptors CD68, 
SRA-1, SRB-1 and LOX-1 also have roles in apoptotic cell 
recognition.64–67
Mechanisms for the recognition of PS are clearly impor-
tant and highlight, once again, the benefits to efficient clear-
ance of dying cells, as defects in PS recognition genes are 
associated with important pathologies. For example in experi-
mental atherosclerosis, a defect in Gas-6 promotes more stable 
plaque development with reduced phagocyte presence,68 pos-
sibly suggesting a role for Gas-6 in phagocyte recruitment/
retention as well as in apoptotic cell clearance. However, 
defects in Mer, to which Gas-6 bridges PS, result in defective 
apoptotic cell clearance and support atherogenesis.69,70  Further 
work is required to explain this apparent paradox. Defects in 
Mer and Tim-4 are also associated with reduced apoptotic cell 
clearance and development of autoimmunity in mice.70,71 PS 
recognition via Gas-6 and MFG-E8 is also implicated in the 
review. However it is clear that the apoptotic cell ligands and 
their cognate phagocyte receptors work as a team (in a phago-
cytic synapse)46 to effect these different stages of the apop-
totic cell clearance pathway, with some players solely involved 
in tethering and others involved in multiple stages (Fig. 2). 
 Figure 5 depicts major molecular players underpinning the 
clearance of apoptotic cells.
As cells enter into apoptosis, ‘eat me’ flags are pre-
sented on the cell surface and are released on extracellular 
vesicles. The flags so far identified encompass exposure of 
intracellular molecules (e.g., phosphatidylserine (PS)47,48 and 
annexin I),49 modification, redistribution and removal of cel-
lular  proteins, lipids and glycoproteins (e.g. modification of 
ICAM-3,50 PS oxidation,51 removal of sialic acid)52 and bind-
ing of  opsonins (e.g. mannan-binding lectin (MBL), C1q).53,54 
Often the  precise nature of molecular modifications that may 
occur during apoptosis remains ill-defined.
PS is the most extensively studied ‘eat me’ marker, 
which in viable cells is restricted to the inner leaflet of the 
plasma membrane and is redistributed during apoptosis.48,55 
This exposure of PS through loss of phospholipid asymmetry 
is required for phagocytic clearance of apoptotic cells.47,48 It 
seems likely that this redistribution of membrane lipids also 
permits the movement of other surface molecules to indi-
rectly promote apoptotic cell clearance. PS has been shown 
to bind to the phagocyte directly through phagocyte recep-
tors T cell immunoglobulin mucin-1 (TIM-1) and TIM-4,56 
brain- specific angiogenesis inhibitor-1 (BAI1),57 stabilin-258 
and the Receptor for Advanced Glycation Endproducts 
(RAGE).59 These receptors are not ubiquitously expressed 
Figure 5. Molecular associations that drive apoptotic cell clearance.
Abbreviations: ShPS-1, Src homology 2 domain-bearing protein tyrosine phosphatase substrate-1; aCaMPs, apoptotic cell-associated molecular 
pattern; aCho, altered carbohydrate; aBC-a1, atP-binding cassette transporter 1; b2GPI, b2-glycoprotein I receptor; BAI-1, brain-specific 
angiogenesis inhibitor 1; Crt, calreticulin; dCD31, disabled CD31; ICaM-3, Intercellular adhesion molecule 3; oxlls, oxidized lDl-like sites; oxPl, 
oxidized phospholipid; PS, phosphatidylserine; raGe, receptor for advanced glycation endproducts; tIM-1/4, t cell Ig and mucin domain-containing 
molecule-1/4; tSP, thrombospondin.
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A role for immunoglobulin in dead cell removal through 
opsonisation of dying cells has been demonstrated.91,92 Poly-
reactive IgM antibodies play a role in this by binding to 
ligands on dead cells and much of the focus of such studies 
have addressed the role of IgM as a mediator of complement 
opsonisation to promote AC clearance.91,93 However, IgM has 
also been suggested to promote AC clearance in the absence 
of complement activation.94 These studies have also tended 
to focus on the clearance of late apoptotic cells/secondary 
necrotic cells, highlighting how different clearance pathways 
may be tailored to a certain phase of cell death. IgM has also 
been recently reported to promote the clearance of extracellu-
lar vesicles (microparticles) released by apoptotic cells,95 pos-
sibly implicating IgM in phagocyte responses to these (e.g., 
in chemoattraction). IgG-based immune complexes have also 
been suggested to opsonise apoptotic neutrophils to promote 
their clearance.96
It has been shown that many viable cells constitutively 
express ‘eat me’ markers without being engulfed by phago-
cytes, suggesting that they are not sufficient for clearance, 
and highlight other mechanisms must be in play to tip the 
balance towards recognition.97,98 This counterbalance comes 
through the alteration or down regulation of ‘don’t eat me’ 
signals, expressed on viable cells. These include CD300a,68 
CD3169 and CD47,45 which all vary in mechanism of 
 function. CD300a is newly identified as an inhibitor of AC 
engulfment via competitive phospholipid binding on apop-
totic cells.99,101 CD31 binds homophilically to prevent inges-
tion of viable cells, but its function is altered when CD31 on 
the phagocyte binds disabled CD31 on AC, as this leads to 
AC tethering.100 Mechanisms of CD47 action are more fully 
defined. Found on viable cells, CD47 exerts its inhibitory 
effect via its receptor SIRPα, and clearance in vitro only 
occurs with CD47 disruption.62 Changes in these inhibitory 
molecules allows ‘eat me’ signals to mediate apoptotic cell 
uptake though inappropriate function of inhibitory signals, 
which may lead to failed clearance and subsequent disease; 
for example, immune evasion via CD47 over-expression in 
leukemic cells.102
Signalling and Engulfment
Once the balance of molecules tips towards recognition and 
tethering of the apoptotic cell, several downstream signal-
ling pathways can be activated. This depends largely on the 
specific receptor complexes activated in the phagocytic syn-
apse where a combination of receptor classes is engaged. The 
precise constitution of a phagocytic synapse on any given cell 
is yet to be defined. It seems likely that this will be variable 
depending upon the phagocyte and the target cell, but will 
comprise a sub-group of the array of molecules implicated in 
clearance.
Many apoptotic cell receptors co-localize with oth-
ers for effective clearance, as some function only to tether 
apoptotic cells, and of particular interest are the receptors 
efficient clearance of photoreceptor fragments, a homeostatic 
process central to retinal maintenance. Failed clearance leads 
to death of photoreceptors and degenerative eye conditions.71 
Similarly, Mer kinase is implicated in the pathology of reti-
nitis pigmentosa, where patients may carry a natural muta-
tion in Mer and thus have defective clearance of photoreceptor 
fragments.72 Furthermore, reduced recognition of PS has also 
been implicated in Alzheimer’s disease, where both increased 
neuronal death and reduced clearance, possibly from reduced 
MFG-E8 expression,73 may contribute to the increased  levels 
of apoptosis detectable in the Alzheimer’s disease brain 
(reviewed in71). Loss of integrins has also been associated with 
chronic ulcerative colitis and autoimmunity.74 It is clear that 
efficient clearance of dying cells is essential to prevention of a 
range of important inflammatory diseases, but it is interest-
ing to note that pathology tends to follow disruption of those 
clearance pathways that function to mediate phagocytosis and 
cell responses.1
Other important bridging molecules in clearance have 
been identified, including collectins (MBL/SP-A/SP-D), 
complement components (C1q, C3b), pentraxins (PTX3, 
SAP and CRP), and TSP-1.75–83 Soluble CD14 has also been 
observed to bind PS and AC, but a clear role in promoting 
removal of AC has proved elusive.84 Antibodies also have a 
role in opsonising/bridging of ACs, with a recent study detail-
ing thousands of IgG autoantibodies that are ubiquitous in 
human serum.85
ICAM-3 expressed specifically on human leukocytes is 
another cell surface receptor that becomes modified, at least 
functionally, during apoptosis, providing a ligand for an as yet 
unidentified phagocyte receptor.33,50 It has been proposed that 
ICAM-3 may bind the pattern-recognition receptor (PRR) 
CD14,50 though evidence of a direct interaction is lacking. The 
precise molecular changes that underpin the role of ICAM-3 
as an apoptotic cell-associated ligand and promoter of phago-
cyte recruitment remain ill-defined, but may (as with other 
apoptotic cell ligands) lie in changes of its location on viable 
versus apoptotic cells.
Numerous PRR, which have a role in innate  immunity/
host defense, have been shown to mediate apoptotic cell 
clearance, prompting the hypothesis that some apoptotic 
cell ‘eat  me’ markers are structurally analogous to PAMPs 
(pathogen-associated molecular patterns; e.g., LPS). These 
have been termed apoptotic cell-associated molecular patterns 
(ACAMPs).86,87 Recently anti-PAMP antibodies have been 
used to probe apoptotic cells to identify ACAMPs.88 Scav-
enger receptors are a group of PRRs with identified roles in 
apoptotic cell recognition, with CD14 (the prototypic PRR) 
having a well-established role in responses to LPS through 
its functional association with signalling partner toll-like 
 receptor 4 (TLR4).89 However, CD14 also mediates tether-
ing of  apoptotic cells to phagocytes,84,90 though there has cur-
rently been no noted involvement of TLR4 in CD14-mediated 
binding of AC.
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 inflammation, including TNF-α, IL-1, IL-12 and IL-8.2,116 
Results also showed that apoptotic cells were able to dampen 
a pro-inflammatory response to LPS.2 Other factors also 
play a role, including lipoxins, resolvins and protectins 
(reviewed  in119). At sites of inflammation, where large-scale 
clean-up of apoptotic cells can be expected, resolution is fol-
lowed by immune cell egress into the lymphatic system and 
accumulation in the lymph nodes.40 It has been proposed that 
defective cell egress at inflammatory sites may be exacerbated 
by factors within the local microenvironment,40 e.g., secre-
tion of netrin-1 by macrophages in the atherosclerotic plaque 
may cause leukocyte trapping.10 Targeted netrin-1 deletion 
in murine macrophages promoted macrophage egress and 
reduced atherosclerosis.10
Conclusions and Future Directions
An almost bewildering array of molecular players have been 
implicated in the recognition and removal of apoptotic cells 
though some functional redundancy is apparent.120 In real-
ity, the mix of molecules involved in clearance of any given 
apoptotic target cells by a phagocyte will be a simpler subset 
of those outlined above.
Effective and timely clearance of cells dying by apoptosis 
is a powerful mechanism by which inflammation and auto-
immunity are avoided, despite the constant death of cells in 
vivo. Understanding the balance of molecules and mecha-
nisms that underpin this control is the key to understanding 
many inflammatory disease states. Furthermore, this may lead 
to targeted interventions for the control of these diseases and 
the identification of novel anti-inflammatory therapies. Stud-
ies have shown that immune-modulation can be uncoupled 
from clearance.84,121 Understanding the fine details of phago-
cyte recruitment and the roles of individual mediators within 
the phagocytic synapse may provide direction for future treat-
ments for pathologies including cancers, arthritis and cardio-
vascular disease. Novel treatment strategies will become more 
important as the population ages.
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that recognize multiple ligands but with opposing immu-
nological consequences. For example, CD14 responds in an 
inflammatory manner to ligation with LPS; however, it also 
functions to tether apoptotic cells in a non-inflammatory 
manner.84,90 The precise mechanism by which receptors such 
as CD14 elicit ligand-dependent responses has yet to be fully 
elucidated, but altered signalling partners may provide one 
mechanism.103
Activation of αv integrins,104 the Tyro3, Axl, Mer 
(TAM) family receptor Mer,105 and brain-specific angio-
genesis inhi bitor 1 (BAI1)57 which all recognize PS either 
directly or  indirectly, activates CrkII-Dock180-ELMO 
complex, which initiates Rac activation via GDP-GTP 
exchange.106 This results in Scar/WAVE mediated cytoskel-
etal rearrangement.107,108
LRP-1 and Stabilin-2 binding initiates a second pathway 
via adaptor protein enGULfment adaPter protein (GULP) 
interaction, which activates ABCA1 and/or ABCA7.109–111 
Though the understanding of ABC-binding cassette trans-
porters ABCA1 and ABCA7, involvement is unclear, there 
is evidence that this pathway converges with the CrkII-
Dock180-ELMO pathway at the equivalent of Rac, CED- 10, 
in C. elegans.112 Further signalling pathways have been put 
forward, though research is so far restricted to C. elegans 
models.113
Following engulfment, the phagosome becomes 
acidic and fuses with lysosomes,114 resulting in apoptotic 
cell digestion. This process is key to regulating future 
events including further engulfment potential,115 cytokine 
release2,116 and self-antigen presentation. Even at this late 
stage, defects in clearance mechanisms can have detrimen-
tal effects.117
What Next for the Phagocyte?
The immunological consequences of apoptotic clearance are 
key to the success of the apoptosis program. The benefits of 
ordered cell deletion by apoptosis are evident when contrasted 
to the devastating consequences associated with cell necro-
sis. There seems little logic to expending energy to push a cell 
through apoptosis if the net effect is cell lysis and immune 
activation. Thus, the benefit of apoptosis is realized through 
its associated immune modulation. Apoptotic cell clearance 
promotes a non-inflammatory or actively anti-inflammatory 
response whilst neglect of apoptotic cells allows development 
of secondary necrotic bodies, and unwanted inflammation 
will ensue.118 Full understanding of the balance of interac-
tions that mediates the overall anti-inflammatory nature of 
apoptotic cell clearance could have implications for treatment 
of inflammatory conditions.
Resolution of inflammation is an active process, rather 
than the ebbing of an inflammatory response. The release of 
anti-inflammatory mediators has been reported in response 
to apoptotic ells, including TGF-b1, IL-10, PGE2, and 
PAF, along with suppression of mediators associated with 
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